Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent

Conditions: Solid Tumor, Adult; Solid Tumor; Gastric Cancer; Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Advanced Solid Tumor Interventions: Drug: PB101 Sponsors: Panolos Bioscience Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials